Lecture on Nasal Vaccines by Dr. Mubeen Syed
Introduction
- Speaker: Dr. Mubeen Syed from DrBean.com
- Topic: Nasal Vaccines
- Current Status:
- Some vaccines are in trials; results pending.
- Animal tests show good results with IgG, IgA production, and activation of cytotoxic T cells.
Concerns with Nasal Vaccines
- Side Effects: Potential local reactions in the nose.
- Adenovirus: Used in vaccines; could be attacked by existing antibodies in the body before functioning effectively.
Advantages of Nasal Vaccines
- Stability at room temperature
- Easier transportation and distribution
- Potential for higher IgA production compared to intramuscular vaccines
Technology and Companies
- AstraZeneca (Oxford) and Rokote Labs (Finland)
- Using adenovirus-based technology
- Altimmune
- Also using adenovirus technology; conducting animal studies
- Avalon GloboCare
- Utilizing S-layer technology similar to Novavax
Detailed Technology Insights
Immune Response and Studies
- Altimmune Animal Studies:
- Day 28: High IgG titers, CD8+ T cells, and IgA production
- Demonstrates robust adaptive immune response
Benefits of Nasal Vaccines
- Targets mucosal immunity effectively
- Less dependence on cold storage logistics
Considerations
- Importance of balancing IgA and IgG responses
- Maintaining strong surface immunity to prevent virus entry
Conclusion
- Nasal vaccines offer a promising alternative with logistical and immune response advantages.
- Ongoing trials and research are crucial to determine efficacy and safety.
Dr. Mubeen Syed expresses gratitude for support and donations through various platforms. Encourages further engagement through likes, subscriptions, and other supporting links.